Abstract-Market pressures have driven pharmaceutical companies to reassess their current drug development model and reach out to new innovative business models such as drug repositioning. Various techniques that are used in drug repositioning lend themselves to the distributed computing model. The Cloud is one such computing model that optimizes resource usage and represents the current trend for drug repositioning companies in various pilot projects. Security and provenance of data remains the biggest challenge for wider adoption of the Cloud in drug repositioning.
I. INTRODUCTION
In the current economic environment where reductions in cost and economies of scale are in demand, drug repositioning and Cloud computing are emerging as the next dominant paradigm in drug development and in distributed computing respectively.
In order to realize the profit potential of drug repositioning one must delve into the economics of drug development. The development of a drug has multiple phases starting as a compound selected from a high throughput screening (HTS) procedure. The success rate at this stage is 5-10 lead compounds from 5000-10000 initial compounds. The lead compound is further refined by altering the basic molecule in a chemical manner, maybe in multiple cycles, in order to achieve better efficacy (specificity and affinity) in vitro and in animal testing. This procedure is both expensive and time consuming taking typically 1-6 years [1] , [2] as can be seen in table I. At a later stage the drug enters human testing phases I, II, III where it is tested for both efficacy and safety. It takes 10-15 years, over 1 billion USD (amortized cost between failed drugs) and only one drug in 5 gets the approval from FDA in the US [3] . The enormous increases in research and development (R&D) spending, the dearth of approvals of New Chemical Entities (NCEs) and the competition from generic drugs has driven bio-pharmaceutical companies to evaluate new business paradigms, one of them being Drug Repositioning or Repurposing (DR). DR has traditionally been part of the drug development process as a strategy to preserve and extend the value of patents through reformulation strategies [4] . However, the productivity challenges of traditional drug discovery together with the exemplary success of Viagra which started initially as a drug for coronary artery disease [5] and accidentally found to be effective in erectile dysfunction, put in motion the current trend of drug repositioning [6] .
The basic idea behind drug repositioning is to apply an already known and safe drug to new indications. The potential profits of this are three-fold:
• Time and cost to market: An existing drug can enter Phase II immediately skipping the discovery and Phase I stages.
• Patent protection: A branded drug close to the end of its patent or even a generic drug can get a new life if it is patented for a new indication, especially if this is combined with reformulation strategies. • Risk minimization: A known existing drug will be much less prone to new unexpected adverse reactions and thus the risk of not getting approved significantly smaller. The explosion of bio-informatics data and clinical data has led to the popularity of in silico techniques in drug repositioning. Hence scalable processing power service is desirable in DR. Approaches such as Virtual Screening (VS) [7] , molecular binding simulation [8] or literature based high throughput screening [9] , [10] are CPU bound processes that are highly scalable and parallelizable. The need of scalable processing power can be fulfilled with the use of distributed computing systems of which the Cloud is the latest paradigm.
Due to its industry origin, the term Cloud has no widely accepted and all encompassing definition. The most comprehensible definition according to [11] was found in [12] A large-scale distributed computing paradigm that is driven by economies of scale, in which a pool of abstracted, virtualized, dynamically-scalable, managed computing power, storage, platforms, and services are delivered on demand to external customers over the Internet. Delivery over the internet is the key difference with comparison to older distributed computing technologies [11] . After all the term Cloud comes from the typical depiction of Internet in network diagrams.
Cloud computing, as it is modeled today by Amazon's EC2 [13] for example, is a pay as you use service that optimizes utilization of available computing resources. The Cloud momentum is backed by very big companies and the relevant infrastructure technologies being developed are proprietary. The corporate backing helps to create a service which is gaining traction as a consequence of being easy to use and pay for. Due to the powerful network effects, that govern the IT industry, the Cloud trend is transforming computing to a commodity, and may in the future turn it into the fifth utility [14] after electricity, water, telephony and gas.
The industry led proprietary commoditization is currently performed without any standardization. This creates fragmentation in the technology and the terminology used, which is further amplified by marketing pressures as every company needs to differentiate its cloud-based products and services from its competitors. However the lack of standards in the Cloud infrastructure technology may lead to vendor lock-in problems in the future. There are efforts to alleviate the current situation both at the specification level [15] , [16] and the implementation level [17] .
It is worth noting that while the Cloud trend is currently driven by the industry, a number of Cloud specific publications have appeared after 2008, indicating the growing interest in the academic world. The existing Clouds build on the theoretical work on distributed computing, namely grids and clusters, from the mid nineties. Recently, however, the extensive penetration of the Clouds in every aspect of computing life poses serious challenges such as data security, privilege access, provenance, user's privacy, vendor lock in. These issues are currently hot research topics [18] - [21] .
In the rest of the paper a technological overview is given covering both existing Cloud architectures and the current drug discovery scene. Finally, real world applications and pilot projects of big pharmaceutical companies in the context of the Cloud computing and drug development are discussed.
II. TECHNOLOGICAL OVERVIEW

A. Cloud Architecture
Cloud computing is a model for providing on demand network access to a pool of highly scalable and dynamically configurable computer resources (data storage, processing, network bandwidth etc.) [11] , [22] , [23] . The user accesses the Cloud from a wide variety of client platforms, mobile phones, personal computers, PDAs, using standard network protocols and mechanisms. The details of the underlying infrastructure are transparent to the user and all resources are automatically managed, usually backed up by virtualization technologies [24] - [27] . The resources are rapidly scaled with minimal or no interaction of the Cloud provider/administrator. Multiple clients are served in parallel, while resources are allocated and released, based on the clients' demand trends. The transparency of this procedure creates the illusion of having "unlimited" resources to use. Cloud systems are also monitoring the usage of the provided resources, for user billing and administration purposes.
B. Comparison of Cloud and Grid
Although Cloud computing is a growing trend in the past few years [13] , [28] - [30] , its technology is an evolution of distributed computing systems, like Grids [31] , [32] . What really differentiates Clouds from earlier attempts to distributed computing, is the focus to achieve cost-effective and convenient to use computer resources. The table II presents a comparison of grid and Clouds technologies based on [11] , [31] , [33] - [36] . The key difference in favor of the Cloud is the application abstraction and encapsulation (configuration, migration, control) achieved through Virtualization allowing on-demand execution of existing applications. Finally there is a critical aspect both systems are challenged from: security and privacy.
C. Drug repositioning and Cloud computing
Bioinformatics has witnessed an explosion of data in the post genomic era. This is largely due to extensive use of high throughput techniques [37] , [38] . As a result databases used in Drug repositioning, such as those with sequence, structure and chemical data, have grown exponentially in size. Further, the body of published literature, available for analysis, has also grown rapidly, as scientists try to keep abreast with the data being generated. With the continued technological advancements [39] and continued interest in the field the size of these databases is likely to continue to grow. Insilico techniques, therefore, have become increasingly popular as compared to more traditional approaches such as High Throughput Screening (HTS).
Despite its popularity, HTS proved to be a cost ineffective solution for drug discovery [40] . Further, with the number of targets increasing, 'brute-force' comparison performed by HTS does not scale. Thus knowledge based approaches, such as Virtual Screening (VS), have gained popularity over the last decade. Virtual screening is an, in-silico, computational technique typically used to reduce the number of compounds for which HTS must be run [41] . The technique involves the use of very large chemical and structural databases, to eliminate compounds less likely to be successful [36] . Broadly speaking there are two categories into which VS techniques can be classified [42] . The first technique involves building a receptor model based on the ligands that bind to it [43] . The model may then be used to find whether or not a ligand will bind to the receptor. The second technique involves running docking simulations to determine the likelihood of a ligand binding to a protein. Of the aforementioned methods, docking is more computationally intensive. In practice virtual screening coupled with HTS is a far more efficient approach to drug discovery [7] .
Literature based filtering is an alternative approach to VS for drug repositioning. Text mining approaches have been extensively used in Bioinformatics, for extracting biological entities and their interactions [44] , [45] . Tools based on this Inherent difficulties to secure sensitive data information can be used to determine known and unknown interactions between entities of interest. In the present context, such literature based tools can be used for quickly ruling out compounds that are unlikely to be successful. The ability to correctly identify high-value compounds based on literature gives the approach certain advantages over the two methods described previously. Firstly, the problem being solved is computationally simpler as compared to dealing with structures. Secondly, it leverages the current 'knowledge' of the scientific community. Approaches that builds interaction networks of knowledge from chemi-nformatics, system biology, and pharmacological databases are discussed at [46] - [48] . The explosion of data has a direct impact on the computational demand in drug repositioning. The three virtual screening approaches described above are bound to require more resources as the database size grows. While the impact of advancements in high-throughput techniques is likely to be least on literature based approaches, there will definitely be an impact. Therefore, in-order to perform at the same level the current methodologies require more computational power [41] . Given the current trends in technology the answer to this demand is Cloud computing.
Cloud computing lends many of its natural advantages to drug repositioning. Using a Cloud gives access to virtually unlimited resources to the user. The type of resources requested could range from computing power to storage or any required combination of the two. It is possible that future Cloud setups will provide access to more exotic hardware resources such as Field Programmable Gate Array (FPGA) clusters etc, similar to the GPU cluster instance supported by Amazon's EC2 [13] . What makes this unlimited resource availability especially attractive is the low initial cost of investment and cost of continuous maintenance. Since the Cloud is already setup by a third-party the user has no cost of acquiring all the hardware that is required. A user merely pays for getting access to the resources. Further, the pay as you use model of payment is designed to benefit the user. Finally, the user can alter the amount of resources used based on requirements. This gives the user a lot of flexibility in developing a work-flow for the task to be performed on the Cloud. Coupled with pay as you use, it promotes efficient utilization of hardware resources such that the most cost effective work-flow can be developed.
There are some issues with using Clouds for drug repositioning. Since Cloud computing technology is still young there are insufficient tools and software support available for common Bioinformatics tasks. In order to facilitate transition of users, from their current computing setups where tools and software exist, this issue must be addressed. Technology observers have noted that porting of applications for Clouds is leading to more fragmented data and creating new challenges in data integration [49] . Ontologies and semantic web are increasingly used to facilitate the data integration from multiple heterogeneous sources [50] - [53] . Given the already existing diversity of data in Bioinformatics, addressing these issues carefully would be essential for widescale adoption of Cloud computing.
The most significant issue in using Cloud technology for drug repositioning is Data security. A comprehensive analysis of Data security issues facing Cloud computing and solutions to some of these problems can be found in [21] . In addition to the already existing threats in todays computing paradigms such as network sniffing, hacking into the data center or phishing etc, there are added concerns when the data is entrusted to a third party as in the case of Cloud computing. Two major concerns are permissions and access of grid administrators and maintaining lineage and provenance of data [11] . While the former hinges entirely on contractual agreements and CSP practices, the latter is a technically challenging issue and currently an open research area.
III. APPLICATIONS
Over the last few years big pharmaceuticals have been assessing storage and computing resources offered by a Cloud.
Several commercial and open-source utility computing setups have arisen, to meet the increasing demand for Cloud computing, many of which are participating in the efforts of pharmaceutical companies. Major pharmaceutical companies like Pfizer, Eli Lilly and Johnson & Johnson have reported successful attempts at using Cloud Computing for drug repositioning tasks [54] . Pfizer working with BioTeam, piloted docking simulations on Amazon's Cloud setup and found the speedup to be significant and cost effective. Lilly working with Cycle Computing and RightScale, used Amazon's EC2 service for piloting sequence analysis on a 64-node cluster. Nimbus Discovery is leveraging Cloud computing through its association with Schrodinger [55] . Nimbus utilizes technology developed by Schrodinger in order to find novel medicines for difficult-to-drug diseases. The partnership has already delivered compounds for targets relevant to Non-Hodgkins Lymphoma and Obesity [56] . Similar collaborations, between large pharmaceuticals and Cloud service providers, could be the basis for a solution to the data security issues discussed in the previous section.
A collaboration of tuberculosis (TB) researchers from across the world is using a Cloud computing platform -CDDfor developing more effective drugs for TB. The work has attracted important collaborations and funding for Collaborative Drug Discovery, Inc [57] , [58] . Molplex provides Cloud based tools and large chemical databases for drug discovery [59] . IBM is looking at an alternative approach to leveraging Cloud computing in the drug industry. 'Clinical Cloud' offers end-to-end clinical solutions with added emphasis on security [60] . Computer technology giant, Oracle, also provides Cloud infrastructure and software support for health care applications [61] . iScreen, developed by the YC Lab, is a Cloud based web server available for drug discovery and repositioning. The web server allows the user to perform docking experiments for virtual screening and also supports de novo drug design [62] .
Biovista (Charlottesville, VA, USA) is also looking at Cloud computing for its drug repositioning demands. Virtual screening and discovery are carried out with the help of a platform, called the Clinical Outcome Search Space TM (COSS), which uses data extracted from literature, cheminformatics and pathway analysis data and data from pharmacological sources. Key aspect of the platform is the custom data retrieval engine which provides fast access to the underlying data. Information extracted from a large body of literature, papers and patents, is recorded in a relational database. The information extraction tools, use a thesaurus to identify biomedical terms in the literature and extract relationships between them. The process of extracting these relationships, to build the high performance database, is highly parallelizable and can take advantage of parallel computing resources such as those offered by Cloud computing. As a part of virtual screening, docking simulations are run using Gromacs [8] . This is a very resource intensive step and is currently run on a cluster of machines. The time requirement, of a docking simulation along with its control experiments, makes it unreasonable for anything but a final validation step for a few targets. This problem can be alleviated through the use of Cloud, which provides greater processing power, enabling greater use of docking simulation in the screening phase of the workflow.
IV. CONCLUSION
Cloud computing with its dynamic resource allocation and its flexible pricing scheme is emerging as a strong candidate for drug repositioning purposes. Especially for startup companies the Cloud is a very attractive proposition with a low barrier to entry. In order to create a level playing field for both Cloud providers and cloud consumers the Cloud standardization must be further developed.
There are certain challenges that have to be addressed before Drug repositioning companies trust their data to the Cloud. The biggest problem is the lack of trust between a company and a Cloud provider. There are several strategies that could be applied to remedy the issue. From a legal standpoint explicit SLAs could be used to bind the provider in what it can do with the client's data. From a technical point of view, advanced algorithms have to be developed that are capable of working with encrypted input and produce encrypted output. On that front, standardization on the security aspects of the Cloud could help immensely. Finally from a business perspective, a collaboration that gives a share of the drug to the Cloud provider, like in the Nimbus -Schrodingher case, could be made.
